Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

JMP Securities Maintains Market Outperform on Intellia Therapeutics, Raises Price Target to $111

JMP Securities analyst Silvan Tuerkcan maintains Intellia Therapeutics (NASDAQ:NTLA) with a Market Outperform and raises the price target from $106 to $111.
byBenzinga Newsdesk
September 19, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

JMP Securities analyst Silvan Tuerkcan maintains Intellia Therapeutics (NASDAQ:NTLA) with a Market Outperform and raises the price target from $106 to $111.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts